AwesomeCapital

Cortexyme up 25% on bullish private stock placement

Thinly traded Cortexyme (CRTX +24.7%) is up in early trade, albeit on below-average volume of only 50K shares, on the heels of its $125M private placement of stock to a group of institutional investors and an entity affiliated with a board member.

The company will issue 2.5M common shares at $50/share, almost a 10% premium to yesterday’s close of $45.64.

Closing date is February 10.

https://seekingalpha.com/news/3539267-cortexyme-up-25-on-bullish-private-stock-placement

Cigna EPS beats by $0.11, beats on revenue

Cigna (NYSE:CI): Q4 Non-GAAP EPS of $4.31 beats by $0.11; GAAP EPS of $2.60 misses by $0.57.

Revenue of $36.54B (+165.7% Y/Y) beats by $1.34B.

Press Release

https://seekingalpha.com/news/3539017-cigna-eps-beats-0_11-beats-on-revenue

Regeneron Pharmaceuticals EPS beats by $0.59, beats on revenue

Regeneron Pharmaceuticals (NASDAQ:REGN): Q4 Non-GAAP EPS of $7.50 beats by $0.59; GAAP EPS of $6.93 beats by $0.71.

Revenue of $2.17B (+12.4% Y/Y) beats by $70M.

Press Release

https://seekingalpha.com/news/3539037-regeneron-pharmaceuticals-eps-beats-0_59-beats-on-revenue

Tonix Pharmaceuticals down 60% premarket on failed Tonmya study

Tonix Pharmaceuticals (NASDAQ:TNXP) has decided to stop enrollment in a Phase 3 clinical trial, RECOVERY, evaluatinng Tonmya (cyclobenzaprine HCl sublingual tablets) 5.6 mg (TNX-102 SL) for the treatment of posttraumatic stress disorder (PTSD).

The company took action after a prespecified interim analysis by the Independent Data Monitoring Committee showed that the study is unlikely to achieve the primary endpoint.

It plans to continue studying the current participants (50% enrolled) until completion, then proceed to a full analysis of the unblinded data to determine next steps. Topline results should be available next quarter.

Tonix will reallocate resources from the PTSD program to the Phase 3 fibromyalgia study of TNX-102 SL 5.6 mg. Interim data are expected in Q3.

Shares down 60% premarket on light volume.

https://seekingalpha.com/news/3539048-tonix-pharmaceuticals-down-60-premarket-on-failed-tonmya-study